Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
267 Treffer:
61.
deCOMPressing stomA and two-Stage elective resection vs. emergency reSection in patients with left-sided obstructive colon cancer
NCT Heidelberg » Für Ärzte » Studien » Gastrointestinale Tumoren » Kolorektales Karzinom
Datum: 2026-04-04
62.
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage, cT1 and cT2N0, Esophageal Adenocarcinoma With Indication for Radical Surgery: A Prospective, Multicenter Study of the FLOT-AIO
NCT Heidelberg » Für Ärzte » Studien » Gastrointestinale Tumoren » Ösophagus- und Magenkarzinom
Datum: 2026-04-04
63.
NeoART - A Phase Ib/II Platform Trial Evaluating the Safety and Activity of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
NCT Heidelberg » Für Ärzte » Studien » Gastrointestinale Tumoren » Ösophagus- und Magenkarzinom
Datum: 2026-04-04
64.
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Gastrointestinale Tumoren » Ösophagus- und Magenkarzinom
Datum: 2026-04-04
65.
Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Entitätenübergreifend/Basket
Datum: 2026-04-04
66.
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?
NCT Heidelberg » Für Ärzte » Studien » Gastrointestinale Tumoren » Hepatobiliäre Tumoren
Datum: 2026-04-04
67.
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors.
NCT Heidelberg » Für Ärzte » Studien » Entitätenübergreifend/Basket
Datum: 2026-04-04
68.
Krebsmedikamente gezielter einsetzen: Erstes EU-Projekt integriert Pharmakogenomik in Tumorboards
Datum: 2026-03-17
69.
Cancer Registry
NCT Heidelberg » Forschung » Core Services NCT Heidelberg » Cancer Registry
Datum: 2026-03-11
70.
Tissue Bank
NCT Heidelberg » Forschung » Core Services NCT Heidelberg » Tissue Bank
Datum: 2026-03-11